Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...

Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared ...

Experts discuss the most common adverse events associated with the FOLFOX regimen and effective strategies for early ...

Experts discuss Robert’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment approaches ...

Key opinion leaders focus on educating patients about potential side effects of lorlatinib and other ALK inhibitors, ...

Medical experts discuss strategies for managing adverse events associated with KRAS-targeted therapies, addressing monitoring ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice.

The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, ...

High PSA Levels Before HIFU May Increase Recurrence Risk in Intermediate-Risk Prostate Cancer ...

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...